MAPK3 and breast carcinoma: In breast cancer patients, phosphorylated ERK1/2 (as determined by immunohistochemistry) may predict a poor response to hormonal therapy and, in a subset of patients, a worse survival (Mueller et al, 2000; Gee et al, 2001).